WESTPORT, Conn., June 22 /PRNewswire/ -- MemoMind Pharma, an affiliate of Austria-based Ebewe Pharmaceuticals, today announced the availability of MemoProve(TM), the first neuropeptide tablet that has been shown to enhance short-term memory in middle-aged and older adults by an average of 15 percent, which is equivalent to reversing 12 years of age-related memory decline according to a leading memory expert.
What Are Age-Related Memory Problems (ARMP)?
After age 25, short-term memory starts a slow steady decline. By age 55, short-term memory in normal health adults may decline 50 percent or more. That’s why most older adults experience age-related memory problems (ARMP), such as misplacing objects, forgetting names, losing focus and struggling with new information. Like graying hair and fading eyesight, ARMP is a normal part of aging, but if it affects your performance at work or your interactions in social situations it can be a cause of great concern.
ARMP is caused by changes in brain chemistry that, with age, expose the neuronal network to degenerative processes. Over time, unprotected neurons and synapses become compromised leading to ARMP. ARMP is a widespread condition affecting nearly 40 million adults over 50, and many younger adults as well. For the first time ARMP can be treated with the neuropeptide preparation in MemoProve that mimics nerve growth factors, and is clinically proven to reverse ARMP.
“Age-related memory problems are a very real issue for millions of adults,” said Thomas Crook, PhD, former Chief of the National Institute of Mental Health’s Geriatric Psychopharmacology Program. “As we all get older, we are extremely fortunate to have this easily-administered neuropeptide tablet available to help counter ARMP and preserve vital memory function.”
Additional information on ARMP and MemoProve as well as short term memory assessment are available at http://www.memoprove.com.
MemoProve Counters the Degenerative Processes that Leads to ARMP
The neuropeptides in MemoProve are similar to those produced by the human body,(1) and can counter the degenerative processes that lead to ARMP by supporting the viability of neurons and stimulating the formation of synaptic connections.(2)
“MemoProve should be of great interest to middle aged adults who are determined to remain productive beyond traditional retirement age,” said Joe Grace, CEO of MemoMind Pharma. “Retaining vital memory function has never been more important to aging adults. MemoProve is the right product at the right time.”
Published Study Shows MemoProve Leads to Improved Memory
In a recent double-blinded, placebo controlled trial published in the peer-reviewed journal International Clinical Psychopharmacology, standardized memory tests were administered to participants at baseline and then again after 30 days. In the study, MemoProve appeared to counter the degenerative processes that lead to ARMP, improving short-term memory by an average of 15 percent.(3) This suggests that the millions of young adults and the majority of adults over the age of 50 who are affected by ARMP(4) now have somewhere to turn for help when they start to notice difficulties with finding misplaced articles, concentrating and retaining new information.
Availability
MemoProve is currently available online at http://www.memoprove.com and by calling 800-739-4664. Future distribution mechanisms planned for this year include fine health retailers, pharmacies and health practitioners. The cost for a 30-day supply of MemoProve is $49.95.
About the Company
MemoMind Pharma was established in 2004 as the sole and exclusive distributor of MemoProve in the United States. MemoMind Pharma’s mission is to raise awareness that age-related memory problems are common and they can be treated with MemoProve. MemoProve(TM) was developed by Austrian-based Ebewe Pharma, an innovative pharmaceutical company specializing in the research and development of therapies for dementia, stroke and cancer. A former division of BASF Pharma and Abbott Labs, Ebewe’s products are available in 70 countries. For more than 30 years, Ebewe has developed a reputation for delivering highly efficacious, science-based prescription products that improve the lives of people around world.
The Food and Drug Administration has not evaluated these statements, and this is not a claim to diagnose, prevent or treat any disease or illness.
(1) Windisch M, et. al.: N-PEP-12 - a Novel Peptide Compound that Protects Cortical Neurons in Culture against Different Age and Disease Assocaited Lesions. In preparation. (2) Levi-Montalcini R. (1987): The nerve growth factor 35 years later, Science 237, 1154-1162. (3) Crook, T. H. et. al. (2005): Effects of N-PEP-12 on memory among older adults, International Clinical Psychopharmacology, 20, 97-100. (4) Larrabee, G. and Crook, T. (1994): Estimated prevalence of Age- Associated Memory Impairment derived from standardized tests of memory function. International Psychogeriatrics, 6, 95-104.
CONTACT: Media: Mynor Herrera, +1-202-518-6560, for MemoMind Pharma, or Business: Joe Grace of MemoMind Pharma, +1-203-349-4412.
Available Topic Expert(s): For information on the listed expert(s), click appropriate link. Thomas Crook III, PhD http://profnet.prnewswire.com/ud_public.jsp?userid=518023
MemoMind Pharma
CONTACT: Media: Mynor Herrera, +1-202-518-6560, for MemoMind Pharma, orBusiness: Joe Grace of MemoMind Pharma, +1-203-349-4412
Web site: http://www.memoprove.com/
